X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8381) 8381
1st-line treatment (8108) 8108
oncology (7737) 7737
chemotherapy (5204) 5204
female (4850) 4850
male (3670) 3670
middle aged (3643) 3643
aged (3604) 3604
cancer (3253) 3253
open-label (2961) 2961
adult (2807) 2807
antineoplastic combined chemotherapy protocols - therapeutic use (2688) 2688
treatment outcome (2681) 2681
1st-line therapy (1972) 1972
care and treatment (1925) 1925
colorectal cancer (1899) 1899
metastasis (1868) 1868
antineoplastic agents - therapeutic use (1815) 1815
fluorouracil (1657) 1657
oxaliplatin (1577) 1577
bevacizumab (1563) 1563
colorectal neoplasms - drug therapy (1553) 1553
survival (1553) 1553
aged, 80 and over (1540) 1540
phase-iii trial (1492) 1492
pharmacology & pharmacy (1465) 1465
mutation (1431) 1431
lung neoplasms - drug therapy (1417) 1417
disease-free survival (1416) 1416
prognosis (1331) 1331
double-blind (1257) 1257
colorectal neoplasms - pathology (1247) 1247
research (1226) 1226
antineoplastic combined chemotherapy protocols - adverse effects (1220) 1220
therapy (1207) 1207
carcinoma, non-small-cell lung - drug therapy (1201) 1201
leucovorin (1186) 1186
trial (1181) 1181
phase-ii trial (1180) 1180
phase-iii (1157) 1157
multicenter (1150) 1150
analysis (1135) 1135
medicine & public health (1118) 1118
drug therapy (1111) 1111
combination (1110) 1110
lung cancer (1109) 1109
clinical trials (1108) 1108
cancer therapies (1092) 1092
neoplasm metastasis (1078) 1078
breast cancer (1043) 1043
neoplasm staging (1031) 1031
gefitinib (1018) 1018
patients (1011) 1011
randomized-trial (1011) 1011
erlotinib (973) 973
retrospective studies (968) 968
irinotecan (959) 959
hematology, oncology and palliative medicine (951) 951
cetuximab (935) 935
breast neoplasms - drug therapy (929) 929
health aspects (909) 909
phase-ii (909) 909
survival analysis (889) 889
tumors (874) 874
cell lung-cancer (870) 870
cisplatin (869) 869
capecitabine (868) 868
1st-line chemotherapy (865) 865
growth-factor receptor (851) 851
lung cancer, non-small cell (837) 837
fluorouracil - administration & dosage (836) 836
hematology (836) 836
lung neoplasms - pathology (783) 783
paclitaxel (776) 776
surgery (775) 775
epidermal growth factor (774) 774
antineoplastic combined chemotherapy protocols - administration & dosage (772) 772
survival rate (768) 768
adenocarcinoma (765) 765
docetaxel (755) 755
efficacy (755) 755
animals (743) 743
metastatic colorectal-cancer (734) 734
lung neoplasms - genetics (730) 730
non-small cell lung cancer (703) 703
deoxycytidine - analogs & derivatives (691) 691
review (685) 685
protein kinase inhibitors - therapeutic use (683) 683
antineoplastic agents (681) 681
randomized controlled trials as topic (655) 655
respiratory system (654) 654
carcinoma, non-small-cell lung - pathology (648) 648
camptothecin - analogs & derivatives (629) 629
organoplatinum compounds - administration & dosage (626) 626
antibodies, monoclonal - therapeutic use (619) 619
5-fluorouracil (617) 617
antimitotic agents (617) 617
carboplatin (608) 608
carcinoma, non-small-cell lung - genetics (607) 607
gastroenterology & hepatology (606) 606
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11749) 11749
French (146) 146
German (125) 125
Japanese (36) 36
Spanish (19) 19
Italian (11) 11
Polish (10) 10
Portuguese (8) 8
Russian (7) 7
Chinese (6) 6
Hungarian (4) 4
Korean (3) 3
Turkish (2) 2
Arabic (1) 1
Czech (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
International journal of clinical oncology, ISSN 1437-7772, 2015, Volume 20, Issue 2, pp. 207 - 239
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2015, Volume 66, Issue 1, pp. 133 - 146
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article